Blog
Cars.com (CARS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Cars.com (CARS) reported $181.57 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 1.1%. EPS of $0.48 for the same period compares to $0.41 a year
Wall Street Analysts See Toast (TOST) as a Buy: Should You Invest?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)
Cameco (CCJ) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)
Is Gray Media (GTN) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm
Compared to Estimates, Ralph Lauren (RL) Q2 Earnings: A Look at Key Metrics
Ralph Lauren (RL) reported $2.01 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 16.5%. EPS of $3.79 for the same period compares to $2.54 a year
Is It Worth Investing in Boeing (BA) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)
Wall Street Bulls Look Optimistic About Synchronoss (SNCR): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)
Why JPMorgan Chase & Co. (JPM) is a Top Stock for the Long-Term
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
The Zacks Premium
Brokers Suggest Investing in Interactive Brokers (IBKR): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)
Americold Realty Trust (COLD) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
For the quarter ended September 2025, Americold Realty Trust Inc. (COLD) reported revenue of $663.67 million, down 1.6% over the same period last year. EPS came in at $0.35, compared to -$0.01 in
Advantage Solutions Inc. (ADV) Q3 Earnings and Revenues Lag Estimates
Advantage Solutions Inc. (ADV) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.03 per share a year ago
Earnings Growth & Price Strength Make Goldman Sachs (GS) a Stock to Watch
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
The Zacks Premium
Kohl's (KSS) Crossed Above the 50-Day Moving Average: What That Means for Investors
Kohl's (KSS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KSS broke out above the 50-day moving average, suggesting a
Wall Street Analysts See Palo Alto (PANW) as a Buy: Should You Invest?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)
CRWV Stock Before Q3 Earnings: Smart Bet or Risky Move for Investors?
CoreWeave, Inc. (CRWV) is scheduled to report third-quarter 2025 results on Nov. 10, after market close.
The Zacks Consensus Estimate for the bottom line in the to-be-reported quarter is pegged at a
Netlist, Inc. (NLST) Reports Q3 Loss, Beats Revenue Estimates
Netlist, Inc. (NLST) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.04 per share a year ago. These figures
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals RXRX reported a loss of 36 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 38 cents. The company had incurred a loss
CION Investment Corporation (CION) Beats Q3 Earnings and Revenue Estimates
CION Investment Corporation (CION) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.4 per share a year
Exploring Analyst Estimates for The RealReal (REAL) Q3 Earnings, Beyond Revenue and EPS
Wall Street analysts expect The RealReal (REAL) to post quarterly loss of -$0.14 per share in its upcoming report, which indicates a year-over-year decline of 55.6%. Revenues are expected to be
Stay Ahead of the Game With Evolution Petroleum (EPM) Q1 Earnings: Wall Street's Insights on Key Metrics
The upcoming report from Evolution Petroleum (EPM) is expected to reveal quarterly earnings of $0.02 per share, indicating no change from the year-ago quarter. Analysts forecast revenues of $21.7
Amdocs (DOX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
In its upcoming report, Amdocs (DOX) is predicted by Wall Street analysts to post quarterly earnings of $1.82 per share, reflecting an increase of 7.1% compared to the same period last year
Dentsply International (XRAY) Lags Q3 Earnings Estimates
Dentsply International (XRAY) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.5 per share a year ago
Unlocking Q3 Potential of American Public Education (APEI): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts forecast that American Public Education (APEI) will report quarterly loss of -$0.09 per share in its upcoming release, pointing to a year-over-year decline of 325%. It is
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.04 per share a year ago. These



